This process enhances the production of insulin-like growth factor binding protein-7 (IGFBP7), which directly impairs insulin receptor signaling in the liver, leading to IR and metabolic-associated MASLD [43,88]. This evidence concerns the gene IGFBP7 and metabolic dysfunction-associated steatotic liver disease.